Miltenyi & Chimera
We ensure your assay stability prior to validation.
Label-Free Interaction Analysis in Complex Matrices
Selection of optimal reagents
(Antibodies, Capture/Detection pairs) based on true binding performance.
Prediction of assay robustness
by analyzing stability and off-rates under realistic conditions.
Reduction of development cycles
by eliminating trial-and-error steps.
Rethink Assay Stability
New Services
Label-Free Interaction Analysis in Complex Matrices
Works in serum, plasma, or cell culture media without purification
Direct Assay Development in Biological Matrices – No Purification Required
This advantage is critically important for customers, especially in drug discovery and diagnostics, as it bridges the gap between in vitro and in vivo conditions.
Benefits for Customer Assays:
-
Elimination of Assay Preparation Time:
-
Customers no longer need to purify their target proteins or ligands from complex media (such as serum, plasma, cell culture supernatants, or even cell lysates).
-
This drastically reduces the time and cost involved in the assay development process and accelerates the validation of drug candidates.
-
-
Increased Biological Relevance and Accuracy:
-
Focal Molography (FM) allows for the measurement of binding constants (K_D, k_{on}, k_{off}) directly in the native environment (“In-Matrix”). This ensures that the interactions occur under physiological conditions defined by ionic strength, viscosity, and the presence of confounding proteins.
-
Unlike many traditional label-free methods that rely on simplified buffers, customers receive more biologically relevant data, minimizing the risk of misinterpreting affinities (e.g., due to buffer artifacts). As stated in the provided documents, this yields “Real Samples, Real Results.”
-
-
Robust Quantification Capability:
-
FM technology can determine not only kinetics but also the concentration of the target protein in complex matrices (as described in the Dirscherl et al. 2025 document).
-
Customer Value: This is ideal for pharmacokinetic (PK) studies or bioprocess monitoring, as concentration measurements can be performed directly within the sample without the matrix interfering with the measurement or requiring high dilutions.
-
In summary: Customers can develop their assays to reflect real biological conditions from the very beginning. This leads to more reliable data and accelerated translation of research findings into clinical or diagnostic applications.
High sensitivity (picomolar levels) and stability
Customer Benefits: High Sensitivity & Stability
1. Accelerated and De-risked Early Clinical Phases
| Benefit | Description | Impact for the Customer |
| Detection of Low Doses (PK/PD) | Picomolar sensitivity allows the detection of biopharmaceuticals and metabolites even after extremely low doses (e.g., First-in-Human studies). | You can use smaller starting doses to enhance safety. Validation of PK/PD correlations is possible earlier, saving time and costs. |
| Detection of Low-Abundance Biomarkers | Even critical, hard-to-detect biomarkers present in biological fluids only in ultra-trace amounts are measured precisely. | Enables earlier and more precise diagnoses or more selective patient stratification for clinical trials. |
| Reduced Sample Volume (Microsampling) | High sensitivity allows the use of minimal sample volumes (e.g., Microsampling). | Logistical simplification of sample collection (e.g., capillary blood), improved animal ethics (3Rs principle), and easier handling of rare or difficult-to-access matrices. |
2. Regulatory Certainty and Reliability
| Benefit | Description | Impact for the Customer |
| GLP/GCP-Compliant Data Quality | The inherent stability of the assays ensures reproducible and robust results over months and across different laboratories. | Regulatory confidence: GLP/GCP-compliant data reduces the risk of queries and delays during submissions (e.g., FDA, EMA). |
| Elimination of Matrix Effects (AnySource®) | Technologies like AnySource® ensure that sensitivity is maintained even in complex and variable biological matrices (e.g., plasma, CSF, synovial fluid). | High reliability and universal applicability of the assays, regardless of the sample type. |
| Wide Dynamic Range | Extreme high sensitivity combined with a broad measurement range (often 3-6 log units with Imperacer®). | Only a single assay is needed to accurately measure both extremely low (early samples) and very high concentrations (late samples), reducing the number of required assays. |
3. Efficiency and Flexibility in Assay Design
| Benefit | Description | Impact for the Customer |
| Efficient Polyplexing | High sensitivity is often compatible with multiplex analysis (Polyplexing). | Deeper informational value from a single, small sample by simultaneously measuring multiple analytes (e.g., PK and various biomarkers). |
| Platform Expertise | Chimera Biotec selects the optimal platform (e.g., Imperacer®, Simoa®, MSD) based on the required sensitivity and stability. | The client receives the best technical solution for their specific bioanalytical challenge, rather than being restricted to a single, suboptimal technology. |
In summary:
Clients of Chimera Biotec maximize information gain from their valuable samples (thanks to picomolar sensitivity), accelerate their studies (thanks to microsampling and wide measurement range), and increase their regulatory confidence (thanks to robust stability and GLP/GCP compliance).
Which specific type of biomarker or therapeutic molecule are you most interested in exploring in the context of this technology?
Multiplex (up to 64 interactions in parallel)
Customer Benefits: Multiplex (Up to 64 Interactions)
1. Data Quality and Scientific Insight
| Benefit | Description | Impact for the Customer |
| Holistic Biological View | Simultaneous measurement of 64 biomarkers, cytokines, PK drugs, or Anti-Drug Antibodies (ADA) provides a complete profile of the cellular environment or immune status. | Complex biological interactions (e.g., cytokine cascades or the tumor microenvironment) become visible, which are missed by single assays. This enables better Mechanism of Action (MoA) elucidation. |
| Intrinsic Internal Control | All 64 analytes in a single well or reaction are measured under identical sample and reaction conditions. | Drastically reduces inter-assay variability. Comparisons between the 64 measurements are intrinsically more reliable than comparing 64 single ELISAs run on different days with different reagents. |
| Identification of Biomarker Signatures | Parallel analysis is fundamental for searching for correlated biomarker patterns (signatures) instead of relying on single markers. | Leads to more precise predictive and prognostic biomarkers and supports the development of Companion Diagnostics. |
2. Operational and Economic Efficiency
| Benefit | Description | Impact for the Customer |
| Massive Reduction in Sample Consumption | Instead of 64 separate samples (for 64 single ELISAs), only one tiny sample is required for all 64 interactions. | Critical for studies with limited sample material (e.g., pediatric studies, CSF, biopsies). Preserves valuable patient samples and allows more analyses from existing material. |
| Significant Time and Cost Savings | The effort for 64 separate pipetting steps, incubations, washes, and readouts is reduced to a single assay run. | Enormously accelerates the entire analysis workflow. Reduces labor costs and reagent consumption per data point. |
| High-Throughput Capability | The method is ideal for screening large cohorts or for High-Throughput Screening (HTS) in early drug discovery. | Enables the study of statistically significant sample sizes quickly and cost-effectively. |
3. Flexibility and Robustness
| Benefit | Description | Impact for the Customer |
| Modular Assay Design | The multiplex platform allows assay panels to be flexibly adapted to the specific clinical question (e.g., switching from a cytokine panel to a PK/ADA panel). | Customers can quickly respond to new study results and adjust analytical panels without lengthy re-development. |
| Efficiency in Diagnostics | For infectious diseases or autoimmune disorders, up to 64 pathogens, antibodies, or mutations can be captured in a single test. | Accelerates diagnosis and enables clinicians to make informed therapeutic decisions faster. |
In summary:
The ability to measure up to 64 interactions in parallel transforms bioanalytics from a sequential (single measurement after single measurement) to a parallel and data-rich science. Customers gain deeper biological insights with lower sample consumption and a massive increase in process efficiency.
Are you interested in how this 64-plex approach can be specifically applied in an area like oncology or immunotherapy?
your study your needs
Kit & individual developed based
We offer kit-based as well as individually created designs to meet every need.
Get your offer
Short reagent design workflow
Inhouse reagent design
We can customize the design of the required reagents in-house, tailored to the needs of your study.
Ask a scientistHow can you measure Protein Interactions?
Biomolecular interaction analysis (BIA)
What is BIA?
Biomolecular interaction analysis (BIA) and label-free detection are essential techniques in the field of molecular biology and biotechnology. They involve studying the interactions between biomolecules, such as proteins, DNA, and small molecules, without the need for fluorescent, radioactive or other labels. Instead, these methods rely on various physical and chemical principles to directly observe and quantify binding events. Label-free detection techniques provide real-time, quantitative data on binding affinity, kinetics, and specificity, making them a valuable tool in drug discovery, molecular biology research, and diagnostics. They offer insights into the involvements of molecular interactions and are essential for understanding biological processes and designing novel therapeutics.
384 well plates
up to 2 x 384 well plates
Multiplex 64
Characterize 64 interactions simultaneously
Reducing fears
Success can be planned
By selecting the appropriate proteins in advance, we significantly reduce the risk of study failure, as we greatly increase the stability of the assay.
Assays that have been tested by us in advance have a 98% higher probability of success.
For LBA
- True “In-Matrix” Kinetics Without Purification
- Elimination of Misinterpretations Due to Nonspecific Binding
- Analysis of “Difficult” and Sticky Molecules
- Label-Free Real-Time Kinetics (k_{on}, k_{off}) Instead of Just Endpoint Data
- Efficient Validation of DNA-Encoded Libraries (DEL)
- Robust Quantification in Complex Media
Focal molography vs SPR
Optical Detection of Molecular Binding:
Why Focal Modulation (FM) is more robust than classical Surface Plasmon Resonance (SPR) due to intrinsic referencing.
| Technology | Core Principle | Measured Change upon Analyte Binding | Referencing Scheme |
| SPR | Incident light excites surface plasmons. The required momentum depends on the refractive index near the surface. | Angle change of the intensity minimum. | External by measuring and digitally subtracting signals from separate channels (mm apart). |
| FM | Coherent light couples into a waveguide and illuminates a mologram (alternating ridges and grooves). | Intensity change of the focal spot (due to coherent diffraction). | Intrinsic (self-referencing) via the wave nature of light across alternating signal and reference regions (sub-micrometer spacing). |
For your Study
Detail overview of advantages
By integrating Focal Molography, Chimera offers its customers a bridge between ultra-sensitive bioanalytics and robust, label-free interaction analysis under physiological conditions.
True “In-Matrix” Kinetics Without Purification
Customers can measure biomolecular interactions directly in complex, physiologically relevant fluids (such as serum, plasma, cell lysates, or whole blood) instead of relying on artificial buffer systems.The Advantage: This eliminates the risk of artifacts caused by protein purification and provides data that much more accurately reflects the biological state within the body (“Real Samples, Real Results”). Customers receive reliable affinity data (K_D) directly from the target molecule’s native environment.
Native Environment
No Purification
Elimination of Misinterpretations Due to Nonspecific Binding
Focal Molography uses a unique, coherent diffraction pattern (“mologram”) that acts as an internal filter. [cite_start]Signals caused by nonspecific binding (NSB) to the sensor surface are physically filtered out because they do not scatter coherently.The Advantage: Customers receive extremely pure binding signals even in “dirty” samples. This solves a major problem of classical technologies like SPR or BLI, where nonspecific binding often leads to false results or unstable baselines.
Pure Signals
No Noise
Analysis of “Difficult” and Sticky Molecules
The technology enables the kinetic characterization of molecules that are highly prone to nonspecific adsorption due to their charge or structure (e.g., positively charged proteins like Granzyme B). Through “Affinity Matching” (backfilling the inactive areas), the sensor is rendered blind to such interfering factors.The Advantage: Chimera can now realize projects for customers that were previously considered “unmeasurable” with conventional label-free methods, without the need for laborious referencing runs.
Difficult Targets
Easily Measurable
Label-Free Real-Time Kinetics (k_{on},k_{off}) Instead of Just Endpoint Data
Unlike classical endpoint assays (such as ELISA), Focal Molography provides detailed kinetic profiles (association and dissociation rates) in real time.The Advantage: Customers understand not only if and how strongly ($K_D$) an active substance binds, but also how fast it binds and how long it remains on the target molecule (residence time). This information is crucial for selecting the best drug candidates in the early phases of drug development.
Real-Time Kinetics
Detailed Dynamics
Efficient Validation of DNA-Encoded Libraries (DEL)
For customers in the field of drug discovery, the technology offers a seamless workflow for validating “hits” from DNA-encoded libraries. The DNA barcodes of the hits can be used directly for immobilization on the chip.The Advantage: Up to 54 different substances (DEL hits) can be characterized simultaneously on a single chip. This massively accelerates the process from hit identification to lead optimization, as resynthesis and purification for validation can often be omitted.
DEL Validation
Efficient Workflow
Robust Quantification in Complex Media
The technology enables not only the determination of affinities but also the direct quantification of target proteins (concentration measurements) in cell culture media or serum with high recovery rates (>99%) and precision.The Advantage: Customers can determine the concentration of biomarkers or therapeutic proteins directly in process fluids or patient samples without matrix effects disturbing the quantification. This is ideal for monitoring protein production or for pharmacokinetic studies.
Precise Quantification
Complex Media
Journey of your assay
Maximum Information Density per Sample (High-Plex)
Advantage: Simultaneous quantification of up to 64 different analytes (e.g., cytokines, chemokines, growth factors) in a single assay run.
Customer Value: Obtaining a holistic immune or tumor microenvironment profile from a single sample. This allows for the discovery of biomarker signatures and complex interactions that are crucial for elucidating the Mechanism of Action (MoA).
Drastic Sample Economy
Advantage: All 64 measurements are obtained from a single, minimal sample volume (e.g., just a few microliters).
Customer Value: Preservation of valuable or limited patient samples (e.g., from biopsies, CSF, rare cohorts). The client can achieve significantly more data points per patient draw.
Superior Reproducibility and Internal Control
Advantage: Parallel measurement occurs under identical reaction and incubation conditions within a single well.
Customer Value: Inter-assay variability is minimized because all 64 measurements are intrinsically comparable. This leads to statistically more robust data for clinical evaluation and regulatory submission.
Analysis of Tissue Microenvironments (Tumors / Inflammation)
Customer Challenge: Analyzing protein expression in solid tissue samples (e.g., tumors, inflamed organs) is challenging due to extremely limited sample volume (small biopsies) and tissue heterogeneity.
Advantage: The sample economy and ability to measure many markers are ideal for processing tissue lysates. The multiplex panel provides a comprehensive profile of tumor/inflammatory markers (e.g., angiogenesis factors, immune checkpoints) from the scarce sample.
Customer Value: Maximized utilization of rare samples. Enables correlative analysis between the tissue protein profile and clinical response, which is crucial for developing predictive biomarkers.
Identifying Immunogenic Signatures
Customer Challenge: In the development of biologics (antibodies, proteins, gene therapies), the patient’s immune response (immunogenicity) must be carefully monitored. It is crucial to know which specific cytokines are released to detect the risk of immune-related adverse events (e.g., cytokine storms) early.
Advantage: The assay can simultaneously:
Measure the PK of the therapeutic drug.
Detect Anti-Drug Antibodies (ADA).
Quantify a panel of 30+ cytokines and chemokines indicative of an immune reaction.
Customer Value: Early, mechanistic detection of unwanted immune responses through a complete profile of the immune response. This allows for faster adjustment of dosing or patient stratification.
Early-Stage Product Candidate Screening (HTS)
Customer Challenge: In early research and development, thousands of potential drug candidates must be rapidly tested for their cellular activity (e.g., the ability to induce or suppress specific markers in cell culture).
Advantage: The high parallelism (up to 64 markers) and high-throughput capability (HTS) of the MatchMaker format allow for simultaneous screening of multiple functional endpoints in every sample.
Customer Value: Massive increase in screening efficiency. Instead of testing markers sequentially, all 64 markers can be assessed in one step. This shortens the time to lead candidate identification and provides deeper insights into their MoA.
Significant Reduction in Time and Cost
Advantage: The workflow of 64 single assays is consolidated into one single multiplex run.
Customer Value: Massive acceleration of the analysis workflow and reduction of laboratory costs (labor time, reagents, plate consumption) compared to running numerous individual ELISAs.